Literature DB >> 17220963

Systems biology: Potential to improve decision making in pharmaceutical development.

Hamza Mujagic1.   

Abstract

On October 5, 2006, the New England Systems Biology Association held its first annual meeting at Bentley College, Waltham, Massachusetts. The meeting was organized under the title "Systems Biology in Drug Discovery" and was devoted to the presentation of current status and advances in this new and ever-expanding field in medical sciences. It brought together biologists, biochemists, physicians, physicists and engineers, as well as leaders in biopharmaceutical industry interested in this field of science and its possible impact on anticancer drug discovery. The meeting consisted of two sessions, one in the morning and one in the afternoon and a panel discussion at noon. Each session hosted four speakers and a panel discussion featuring five discussants. Each session also included keynote speakers. Systems biology can help to identify disease-specific molecules and drug-specific targets. This is especially useful as a new tool in diagnostic approaches and drug discovery. Using specific techniques like gene profiling, marker detection and kinase-specific substrate definition, and combining them with large databases and computational methods it is possible to look at the organism as a complex association of gene activation and control networks, and their products, and thus gain better and more realistic insights into disease processes and into drug mechanisms. Copyright 2006 Prous Science. All rights reserved.

Mesh:

Substances:

Year:  2006        PMID: 17220963

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  2 in total

Review 1.  Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.

Authors:  Kenneth T Luu; Eugenia Kraynov; Bing Kuang; Paolo Vicini; Wei-Zhu Zhong
Journal:  AAPS J       Date:  2013-02-14       Impact factor: 4.009

Review 2.  Cancer epidemiology: study designs and data analysis.

Authors:  N Malats; G Castaño-Vinyals
Journal:  Clin Transl Oncol       Date:  2007-05       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.